马来酸噻吗洛尔眼液联合拉坦前列素眼液对原发性开角型青光眼患者眼压的影响

目的:探讨马来酸噻吗洛尔眼液联合拉坦前列素眼液对原发性开角型青光眼患者眼压的影响。方法:选取2015年1月-2016年5月在我院接受治疗的原发性开角型青光眼患者84例,其中给予马来酸噻吗洛尔眼液治疗的42例记为对照组,给予拉坦前列素眼液联合马来酸噻吗洛尔眼液治疗的42例记为观察组,两组均治疗6个月。对比两组患者治疗过程中的眼压变化情况,并对比两组患者的临床总有效率、药物依从性和并发症情况。结果:观察组治疗2、4、6个月后的眼压均显著低于对照组(P0.05),观察组患者治疗6个月后与治疗前的眼压差值大于对照组(P0.05)。两组患者治疗2、4、6个月后的眼压呈下降趋势,两两比较差异均有统计学意义(P0.05)。观察组的临床总有效率95.24%显著高于对照组的80.95%(P0.05)。两组患者在治疗过程中结膜充血、眼内异物感、眼睛疼痛、视力模糊、味觉异常以及总并发症发生率对比差异不显著(P0.05)。观察组患者的药物依从性比例显著低于对照组(P0.05)。结论:马来酸噻吗洛尔眼液联合拉坦前列素眼液治疗原发性开角型青光眼患者具有较好的临床疗效,可显著降低患者眼压,同时具有较好的安全性,但药物依从性较差。     

马来酸噻吗洛尔联合拉坦前列腺素治疗高眼压型开角型青光眼的效果

目的:探讨马来酸噻吗洛尔联合拉坦前列腺素治疗高眼压型开角型青光眼的临床效果。方法:选取高眼压型开角型青光眼患者210例,随机分为治疗组和对照组,每组各105例。对照组患者给予马来酸噻吗洛尔治疗,治疗组患者给予马来酸噻吗洛尔联合拉坦前列腺素治疗。观察并比较两组患者治疗前后视力改善情况,眼压、视乳头杯盘比值变化情况,眼结膜充血、眼内干涩、角膜点状浸润以及一过性视觉模糊等不良反应的发生情况等。结果:治疗组患者视力改善率为85.7%,对照组为71.4%,治疗组高于对照组,差异具有统计学意义(P0.05);治疗后两组患者眼压、视乳头杯盘比值均明显下降,且治疗组明显低于对照组,差异具有统计学意义(P0.05)。治疗组患者眼结膜充血、眼内干涩、角膜点状浸润以及一过性视觉模糊等不良反应明显低于对照组,差异具有统计学意义(P0.05)。结论:马来酸噻吗洛尔联合拉坦前列腺素治疗高眼压型开角型青光眼能够改善患者视力水平,值得临床推广应用。此外,我们分析其作用可能与降低视乳头杯盘比值有关。     

布林佐胺联合噻吗洛尔治疗开角型青光眼的临床效果观察及安全性评价

目的:探讨布林佐胺联合噻吗洛尔治疗开角型青光眼的临床效果及安全性。方法:选择2016年9月至2018年9月在我院接受治疗的150例开角型青光眼患者,采用抽签法分为观察组(n=76)和对照组(n=74)。对照组给予噻吗洛尔治疗,观察组在对照组的基础上给予布林佐胺治疗。比较两组患者的临床疗效、治疗前后眼压、视野平均光敏度、视野平均缺损、视网膜神经纤维层厚度(RNFLT)、视盘盘沿面积(NRA)、泪膜破裂时间(BUT)、收缩期峰值血流速度(PSV)、舒张末期血流速度(EDV)及阻力系数(RI)水平的变化及并发症的发生情况。结果:治疗后,观察组和对照组总有效率分别为96.72%,79.66%,观察组显著高于对照组(P0.05);观察组眼压、视野平均光敏度、视野平均缺损水平及RI均显著低于对照组(P0.05),PSV、EDV、BUT显著高于对照组(P0.05)。两组并发症总发生率分别为3.95%、9.46%,差异无统计学意义(P0.05)。结论:布林佐胺联合噻吗洛尔用于开角型青光眼患者的效果显著,可有效改善患者眼压、视敏度,且安全性较高。     

布林佐胺与噻吗洛尔滴眼液对新生血管性青光眼患者眼压及血清和房水IL-6、PEDF和VEGF水平的影响

目的:探讨布林佐胺联合噻吗洛尔滴眼液对新生血管性青光眼(NVG)患者眼压及血清和房水中白细胞介素-6(IL-6)、色素上皮衍生因子(PEDF)、血管内皮生长因子(VEGF)水平的影响。方法:选取我院2014年6月～2016年12月择期行手术治疗的86例NVG患者,按照随机数字表法均分为两组。对照组术后采取噻吗洛尔滴眼液治疗,观察组在此基础上加用布林佐胺滴眼液治疗。记录比较两组临床疗效,治疗前后眼压及血清和房水中IL-6、PEDF和VEGF水平的变化及不良反应的发生情况。结果:术后6个月,观察组总有效率为95.3%,较对照组明显升高(79.1%,P0.05)。与术前对比,两组术后7天、6个月时24 h眼压峰值、平均眼压、眼压波动值、血清和房水中IL-6、VEGF水平均显著下降(P0.01),血清和房水中PEDF水平均显著上升(P0.01),且观察组以上眼压指标较对照组同期改善更为明显(P0.01)。对照组和观察组不良反应的发生率对比差异无统计学意义(7.0%vs 11.6%,P0.05)。结论:术后应用布林佐胺联合噻吗洛尔滴眼液治疗NVG患者更能有效降低眼压和控制其波动,调节机体血管生成促进/抑制因子平衡,提高治疗效果,且安全性高。     

Thiolated pectin nanoparticles: Preparation, characterization and ex vivo corneal permeation study

The objective of present study was to prepare thiolated pectin nanoparticles and to evaluate them for ocular delivery. Thiolated pectin nanoparticles were prepared by ionotropic-gelation technique using magnesium chloride as the ionic cross-linker and timolol maleate as the model drug. The results revealed that increasing the concentration of magnesium chloride results in significant increase in particle size, while % entrapment is decreased significantly by increase in the concentration of thiolated pectin. The optimal formulation having particle size of 237 nm and % entrapment of 94.6% was obtained at concentrations of thiolated pectin - 0.01% (w/v) and magnesium chloride - 0.01% (w/v). On comparative evaluation, thiolated pectin nanoparticulate formulation provided significantly higher ex vivo corneal permeation of timolol maleate across the excised goat cornea than the conventional aqueous solution.     

Quantitation of mitomycin C in human ocular tissues by high-performance liquid chromatography–photo-diode array detection

A chromatographic method, which can quantitate mitomycin C (MMC) along with two antiglaucoma drugs, is described. The separation of MMC, alphagan and timolol was performed on a reversed-phase C₁₈ column with water–methanol–trifluoroacetic acid (65:35:0.01, v/v) as the mobile phase. By monitoring at 360, 248 and 296 nm, the lower limits of detection for MMC, alphagan and timolol are, respectively, 1.0, 2.0 and 5.0 ng (injection amount) at three-time S/N ratio. The dynamic ranges of quantitation for the three drugs are, respectively, 1.0 ng–10.0 μg, 2.0 ng–10.0 μg and 5.0 ng–10.0 μg with linearity being larger than 0.9960. This method was applied to the determination of MMC levels in Tenon’s and trabeculum tissues of 10 glaucoma patients. MMC levels in these tissues, which were obtained from glaucoma filtering surgery, were determined following a multiple extraction with methanol. The recovery of MMC for a two-batch extraction was better than 91.2%. The reproducibility of measurement for the MMC levels in these tissues is 2.5–6.0% RSD for triplicate injections. The intra-day variation of retention times for the MMC peaks was less than 1.6% RSD (n=3). The inter-day variation of retention times for the MMC peaks was less than 4.8% RSD (n=3). MMC was detectable in three trabeculum tissues out of 10 cases (ranging from 0.8 to 25.5 ng/mg specimen), while MMC was detected in nine Tenon’s tissues out of 10 cases (ranging from 0.3 to 21.1 ng/mg specimen). The results obtained show that the method is sensitive and selective for the quantitation of MMC.